Literature DB >> 2248892

Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis.

P Petzelbauer1, H Hönigsmann, K Langer, B Anegg, R Strohal, A Tanew, K Wolff.   

Abstract

Forty patients with relapsing plaque psoriasis involving more than 20% body surface were treated either with cyclosporin A (CyA) plus PUVA or the retinoid etretinate plus PUVA (RePUVA). They initially received either CyA (2 weeks) or etretinate (1 week) alone and then PUVA was given concomitantly until complete remission. The patients were monitored over a period of 6 months and any relapse recorded. With each combined treatment regimen, CyA plus PUVA and RePUVA, the patients cleared within comparable periods of time (mean treatment period of 5.3 vs. 4.7 weeks after initiation of therapy and 3.3 vs. 3.7 weeks after initiation of PUVA). However, the cumulative UVA dose required for clearance (110.9 J/cm2 vs. 62.1 J/cm2 (P less than 0.05)) and the incidence of severe and early relapses were significantly higher in the CyA cohort. Within 6 months severe relapses had occurred in 58% of CyA plus PUVA but only in 15% of RePUVA-treated patients (P less than 0.001). This suggests that the CyA plus PUVA regimen as performed in this study is less effective than RePUVA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2248892     DOI: 10.1111/j.1365-2133.1990.tb01481.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Giao Do; Camille Hua; Canelle Mazaud; Catherine Droitcourt; Carolyn Hughes; John R Ingram; Luigi Naldi; Olivier Chosidow; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2017-12-22

Review 2.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Liz Doney; Corinna Dressler; Camille Hua; Carolyn Hughes; Luigi Naldi; Sivem Afach; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2022-05-23

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Liz Doney; Corinna Dressler; Camille Hua; Carolyn Hughes; Luigi Naldi; Sivem Afach; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2021-04-19

6.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Sivem Afach; Liz Doney; Corinna Dressler; Camille Hua; Canelle Mazaud; Céline Phan; Carolyn Hughes; Dru Riddle; Luigi Naldi; Ignacio Garcia-Doval; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2020-01-09

Review 7.  German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

Authors:  A Nast; I Kopp; M Augustin; K B Banditt; W H Boehncke; M Follmann; M Friedrich; M Huber; C Kahl; J Klaus; J Koza; I Kreiselmaier; J Mohr; U Mrowietz; H M Ockenfels; H D Orzechowski; J Prinz; K Reich; T Rosenbach; S Rosumeck; M Schlaeger; G Schmid-Ott; M Sebastian; V Streit; T Weberschock; B Rzany
Journal:  Arch Dermatol Res       Date:  2007-05-12       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.